Results 41 to 50 of about 424,058 (165)

Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients

, 2022
ImportanceIn patients with hematologic malignancies, the immunogenicity of the standard 2-dose mRNA-1273 coronavirus disease 19 (COVID-19) vaccination schedule is often insufficient due to underlying disease and current or recent therapy.
Haggenburg, S., Kater, A. P., van Gils, M. J., van Leeuwen, E. M. M., Beaumont, T., Hofsink, Q., Broers, A. E. C., van Binnendijk, R. S., Haverkate, N. J. E., Burger, J. A., Mutsaers, P. G. N. J., Smits, G. P., van Doesum, J. A., Kootstra, N. A., Heemskerk, M. H. M., Bontkes, H. J., Lissenberg-Witte, B. I., Hazenberg, M. D., Goorhuis, A., Wouters, D., van Meerten, T., Bhoekhan, M. S., Nijhof, I. S., Bouhuijs, J. H., Groen, K., den Hartog, G., Zweegman, S., Rutten, C. E.   +27 more
core   +1 more source

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS

International Journal of Infectious Diseases, 2023
Intro: The US CDC recommends that COVID-19 vaccines may be coadministered with other age-appropriate vaccines. There is limited data assessing outcomes, including reactogenicity, on such co-administration.
A. Naficy, P. Pirrotta, A. Kuxhausen, J. Miller, B. Leav, A. Mwakingwe-Omari   +5 more
doaj   +1 more source

Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination

, 2022
Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy We longitudinally profiled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)–specific serological and memory B cell (MBC ...
Normark, Johan, Garcia, Marina,, Ackerman, Margaret E.,, Ahlm, Clas,, Johnson, Carl E.,, Ahlm, Clas, Christ, Wanda, Normark, Johan,, Walker, Laura M.,, Walker, Laura M., Klingström, Jonas, Kaku, Chengzi I.,, Champney, Elizabeth R.,, Klingström, Jonas,, Kaku, Chengzi I., Christ, Wanda,, Johnson, Carl E., Sakharkar, Mrunal, Sakharkar, Mrunal,, Forsell, Mattias N. E.,, Garcia, Marina, Ackerman, Margaret E., Forsell, Mattias N. E., Champney, Elizabeth R.   +23 more
core   +1 more source

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines

Human Vaccines & Immunotherapeutics, 2023
Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still ...
Thomas E. Hickey, Troy J. Kemp, Jimmie Bullock, Aaron Bouk, Jordan Metz, Abigail Neish, James Cherry, Douglas R. Lowy, Ligia A. Pinto   +8 more
doaj   +1 more source

Breakhthrough Infection Pasca Pemberian Booster mRNA Heterolog pada Tenaga Kesehatan di RSUD Arifin Achmad

Majalah Kedokteran Andalas, 2023
Tujuan: Mengetahui prevalensi dan karakteristik responden breakthrough infection pada tenaga kesehatan di RSUD Arifin Achmad Provinsi Riau dalam 14 hari – 6 bulan pasca vaksinasi booster mRNA-1273. Metode: Metode penelitian cross sectional yang dilakukan
Dina Br Nababan, Eka Bebasari, Ligat Pribadi Sembiring, Dani Rosdiana, Rahmat Azhari Kemal   +4 more
doaj   +1 more source

Attenuated activation of pulmonary immune cells in mRNA-1273–vaccinated hamsters after SARS-CoV-2 infection

, 2021
The mRNA-1273 vaccine is effective against SARS-CoV-2 and was granted emergency use authorization by the FDA. Clinical studies, however, cannot provide the controlled response to infection and complex immunological insight that are only possible with ...
Mire, Chad E., Chen, Xi, Periasamy, Sivakumar, Bock, Kevin W., Wang, Yuan, Troyanskaya, Olga G., Carfi, Andrea, Woods, Angela, Zaslavsky, Elena, Rubenstein, Aliza B., Pietzsch, Colette, Ramos, Irene, Shi, Pei-Yong, Ma, LingZhi, Graham, Barney S., Minai, Mahnaz, Sealfon, Stuart C., Ramanathan, Palaniappan, Meyer, Michelle, Ge, Yongchao, Cheng, Wan Sze, Edwards, Darin, Smith, Gregory R., Nagata, Bianca M., Bukreyev, Alexander, Henry, Carole, Stewart-Jones, Guillaume B.E., Moore, Ian N.   +27 more
core   +1 more source

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults

Human Vaccines & Immunotherapeutics, 2023
This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e ...
Patrick Yassini, Mark Hutchens, Yamuna D. Paila, Lorraine Schoch, Anne Aunins, Uma Siangphoe, Robert Paris   +6 more
doaj   +1 more source

Baseline characteristics of 2-dose mRNA-1273 vaccinated and unvaccinated cohort.

, 2022
Baseline characteristics of 2-dose mRNA-1273 vaccinated and unvaccinated cohort.
Katia J. Bruxvoort (12476079), Yun Tian (411157), Hung Fu Tseng (12476097), Ana Florea (12476073), Gina S. Lee (12476085), Jennifer H. Ku (12476088), Yi Luo (143206), Lei Qian (292302), Bradley K. Ackerson (12476082), Julia E. Tubert (12476091), Lina S. Sy (12476076), Carla A. Talarico (12476094)   +11 more
core   +1 more source

Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP. [PDF]

, 2023
OBJECTIVE: To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and mRNA-1273 (Moderna) covid-19 vaccines during the booster programme in England. DESIGN: Matched cohort study, emulating a comparative effectiveness trial.
Parker, Edward PK, Curtis, Helen J, Keogh, Ruth H, Bacon, Sebastian CJ, Palmer, Tom M, Mehrkar, Amir, Sterne, Jonathan A C, Alex J Walker, Williamson, Elizabeth J., Williamson, Elizabeth J, Miguel A Hernán, Brian MacKenna, Ben Goldacre, Elizabeth J Williamson, Jonathan A C Sterne, Horne, Elsie M F, Colm D Andrews, Walker, Venexia M, Jessica Morley, Sebastian C J Bacon, Horne, Elsie MF, MacKenna, Brian, Goldacre, Ben, Hernán, Miguel A, Sterne, Jonathan AC, William J Hulme, Ruth H Keogh, Walker, Venexia, Helen J Curtis, Andrews, Colm D, Edward P K Parker, Amir Mehrkar, Mehrkar-Asl, Amir, Morley, Jessica, Elsie M F Horne, Venexia Walker, Tom M Palmer, Hulme, William J, Walker, Alex J, Goldacre , Ben   +39 more
core   +1 more source

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)

International Journal of Infectious Diseases
Objectives: To assess the safety and immunogenicity of a fourth vaccination (second booster) in individuals aged ≥75 years. Methods: Participants were randomized to BNT162b2 (Comirnaty, 30 µg) or messenger RNA (mRNA)-1273 (Spikevax, 100 µg).
Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, Kristin Greve-Isdahl Mohn, Antonio-José Carcas-Sansuan, Esperanza Romero Rodriguez, José Moltó, Itziar Vergara Mitxeltorena, Tobias Welte, Birutė Zablockienė, Murat Akova, Ullrich Bethe, Sarah Heringer, Jon Salmanton-García, Julia Jeck, Lea Tischmann, Marouan Zarrouk, Arnd Cüppers, Lena M. Biehl, Jan Grothe, Sibylle C. Mellinghoff, Julia A. Nacov, Julia M. Neuhann, Rosanne Sprute, Jesús Frías-Iniesta, Riya Negi, Colette Gaillard, Gurvin Saini, Alejandro García León, Patrick W.G. Mallon, Christine Lammens, An Hotterbeekx, Katherine Loens, Surbhi Malhotra-Kumar, Herman Goossens, Samir Kumar-Singh, Franz König, Martin Posch, Philipp Koehler, Oliver A. Cornely   +39 more
doaj   +1 more source